Summary
115.55 -1.41(-1.20%)09/17/2024
Novartis AG (NVS)
Novartis AG (NVS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.22 | -1.23 | -0.27 | 10.05 | 20.45 | 13.20 | 43.62 | 829.42 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 115.55 | |
| Open | 116.10 | |
| High | 116.10 | |
| Low | 114.98 | |
| Volume | 636,694 | |
| Change | -1.43 | |
| Change % | -1.22 | |
| Avg Volume (20 Days) | 1,057,616 | |
| Volume/Avg Volume (20 Days) Ratio | 0.60 | |
| 52 Week Range | 92.19 - 120.92 | |
| Price vs 52 Week High | -4.45% | |
| Price vs 52 Week Low | 25.33% | |
| Range | -0.48 | |
| Gap Up/Down | -0.87 | |
Fundamentals | ||
| Market Capitalization (Mln) | 226,365 | |
| EBIDTA | 18,944,000,000 | |
| PE Ratio | 23.2045 | |
| PEG Ratio | 5.0912 | |
| WallStreet Target Price | 114.51 | |
| Book Value | 19.4450 | |
| Earnings Per Share | 4.4000 | |
| EPS Estimate Current Quarter | 1.6700 | |
| EPS Estimate Next Quarter | 1.8100 | |
| EPS Estimate Current Year | 7.2700 | |
| EPS Estimate Next Year | 8.0300 | |
| Diluted EPS (TTM) | 4.4000 | |
| Revenues | ||
| Profit Marging | 0.3194 | |
| Operating Marging (TTM) | 0.3078 | |
| Return on asset (TTM) | 0.0865 | |
| Return on equity (TTM) | 0.1983 | |
| Revenue TTM | 47,732,998,144 | |
| Revenue per share TTM | 23.1680 | |
| Quarterly Revenue Growth (YOY) | 0.0970 | |
| Quarterly Earnings Growth (YOY) | 0.2150 | |
| Gross Profit (TTM) | 36,744,000,000 | |
| Dividends | ||
| Dividend Share | 3.9190 | |
| Dividend Yield | 0.0370 | |
| Valuations | ||
| Trailing PE | 23.2045 | |
| Forward PE | 13.2450 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.0962 | |
| Revenue Enterprise Value | 4.4105 | |
| EBITDA Enterprise Value | 11.2733 | |
| Shares | ||
| Shares Outstanding | 2,040,409,984 | |
| Shares Float | 1,949,077,797 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 6.98 | |
09/18 04:24 EST - cnbc.com
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs. CEO Vas Narasimhan said the company was researching treatments that deal with the secondary effects of weight loss, but that it does not plan to compete directly with Novo Nordisk and Eli Lilly.
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs. CEO Vas Narasimhan said the company was researching treatments that deal with the secondary effects of weight loss, but that it does not plan to compete directly with Novo Nordisk and Eli Lilly.
09/17 13:11 EST - zacks.com
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.
09/17 12:55 EST - globenewswire.com
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy 1 ,2 Kisqali ® (ribociclib) significantly reduced the risk of recurrence by 25% vs.
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy 1 ,2 Kisqali ® (ribociclib) significantly reduced the risk of recurrence by 25% vs.
09/17 10:55 EST - zacks.com
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
09/16 10:27 EST - investopedia.com
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
American depositary receipts (ADRs) of Novartis (NVS) gained Monday as new research showed the company's breast cancer treatment, Kisqali, produced longer success than originally thought.
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
American depositary receipts (ADRs) of Novartis (NVS) gained Monday as new research showed the company's breast cancer treatment, Kisqali, produced longer success than originally thought.
09/16 04:15 EST - globenewswire.com
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
Basel, September 16, 2024 – In an updated analysis from the pivotal Phase III NATALEE trial, investigational Kisqali® (ribociclib) added to endocrine therapy (ET) shows a deepening benefit beyond the three-year treatment period, reducing the risk of recurrence by 28.5% (HR=0.715; 95% CI 0.609–0.840; P
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
Basel, September 16, 2024 – In an updated analysis from the pivotal Phase III NATALEE trial, investigational Kisqali® (ribociclib) added to endocrine therapy (ET) shows a deepening benefit beyond the three-year treatment period, reducing the risk of recurrence by 28.5% (HR=0.715; 95% CI 0.609–0.840; P
09/12 11:50 EST - zacks.com
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
09/11 12:13 EST - benzinga.com
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
09/06 10:26 EST - zacks.com
Novartis to License VYGR's Capsid for Gene Therapy in Neurology
NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target.
Novartis to License VYGR's Capsid for Gene Therapy in Neurology
NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target.
09/05 14:34 EST - benzinga.com
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
Goldman Sachs has downgraded Novartis AG NVS, citing “limited value driving innovation catalysts in the near term.”
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
Goldman Sachs has downgraded Novartis AG NVS, citing “limited value driving innovation catalysts in the near term.”
09/04 12:45 EST - zacks.com
NVS or LLY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Novartis (NVS) or Eli Lilly (LLY). But which of these two stocks presents investors with the better value opportunity right now?
NVS or LLY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Novartis (NVS) or Eli Lilly (LLY). But which of these two stocks presents investors with the better value opportunity right now?
09/03 13:01 EST - zacks.com
Novartis (NVS) Upgraded to Buy: Here's What You Should Know
Novartis (NVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Novartis (NVS) Upgraded to Buy: Here's What You Should Know
Novartis (NVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
08/29 10:51 EST - zacks.com
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.
08/28 01:15 EST - globenewswire.com
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy achieved clinically meaningful and statistically significant low-density lipoprotein cholesterol (LDL-C) lowering versus both placebo and ezetimibe in patients who were at low or moderate risk of developing atherosclerotic cardiovascular disease (ASCVD) and not receiving lipid-lowering therapy1.
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy achieved clinically meaningful and statistically significant low-density lipoprotein cholesterol (LDL-C) lowering versus both placebo and ezetimibe in patients who were at low or moderate risk of developing atherosclerotic cardiovascular disease (ASCVD) and not receiving lipid-lowering therapy1.
08/26 10:21 EST - investors.com
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.
08/24 08:14 EST - reuters.com
Siemens Healthineers to buy Novartis unit for over $223 million, FT reports
Siemens Healthineers will pay more than 200 million euros ($223.8 million) to acquire the diagnostic arm of Advanced Accelerator Applications, owned by Novartis , the Financial Times reported on Saturday.
Siemens Healthineers to buy Novartis unit for over $223 million, FT reports
Siemens Healthineers will pay more than 200 million euros ($223.8 million) to acquire the diagnostic arm of Advanced Accelerator Applications, owned by Novartis , the Financial Times reported on Saturday.
08/19 13:57 EST - invezz.com
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.
08/18 10:45 EST - fool.com
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
Despite DexCom's recent challenges, it still has ample growth opportunities. Novartis is a reliable dividend payer that recently changed its business for the better.
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
Despite DexCom's recent challenges, it still has ample growth opportunities. Novartis is a reliable dividend payer that recently changed its business for the better.
08/15 11:20 EST - zacks.com
Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?
Novartis' (NVS) efforts to ward off generic competition for its top cardiovascular drug, Entresto, face a setback.
Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?
Novartis' (NVS) efforts to ward off generic competition for its top cardiovascular drug, Entresto, face a setback.